Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76

Context Therapeutics Inc.

Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.
FDA cleared IND for CTIM-76 (CLDN6 x CD3 bispecific) for Phase 1 in CLDN6-positive gynecologic/testicular cancers.
First patient enrollment for dose escalation expected mid-2024; Phase 1 study to enroll up to 70 patients.
Proceeds plus existing cash extend cash runway into 2028, covering estimated Phase 1 trial duration.
Private placement led by Nextech, with participation from Ally Bridge, Avidity, Blackstone, Blue Owl, etc.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Context Therapeutics Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $100 million (effective 2024-05-01).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: approximately $100 million
Effective: 2024-05-01

Exact text from the filing

On May 1, 2024, Context Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 59,032,259 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.55 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 5,482,741 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $1.549 per Pre-Funded Warrant.

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-24-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.